drugset / Trial / NCT02051621

Therapy of Atrial Flutter by Afib Ablation

NCT02051621 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

Ablation of the cavotricuspid isthmus (CTI) in the right atrium is currently the therapy of choice for the treatment of typical atrial flutter (3,4). It is a curative approach and has a high success rate (5). It has been recognized that patients with typical atrial flutter often complain of atrial fibrillation (1,2). Current clinical and experimental studies confirm the close relationship between atrial flutter (AFL) and atrial fibrillation (AF) and raise a question, if both arrhythmias are different forms of a common electrical phenomenon with atrial fibrillation being the underlying clinical problem (6).

Timeline

Start
2010-08
Primary completion
2015-08
Completion
2017-08

Outcome

Met primary endpoint

paper 14 of 23 patients (60.9%) in the CTI group, and 2 of 20 patients (10%) in the PVI group reached the primary end-point (P <.001) PMID 25638698 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Amiodarone Small molecule 200 mg —
Subject flecainide Small molecule 100 mg —
Subject propafenone Unknown 150 mg —